Extended Data Fig. 5: The number of standard of care (left) or investigational (right) biomarkers per biopsy, for patients included in the DRUP study (blue) vs all others (orange).
From: Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
The y-axis denotes the percentage of biopsies relative to the total number of biopsies from patients in the DRUP study (blue; n = 140 biopsies) or all other patients (orange; n = 341 biopsies). Some patients included in the DRUP study lack actionable biomarkers, for two reasons. First, some patients were included in the DRUP study based on a high tumor mutational burden, which is not considered as an actionable biomarker in the current study. Second, some patients were included in the DRUP study based on the absence of a particular resistance marker (for example, the absence of a KRAS mutation), without the need for the presence of a particular biomarker. Wilcoxon rank sum test-based two-sided P-values are shown.
